- Home
- VXRT
VXRT
Vaxart Inc
as 11-15-2024 4:00pm EST
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 200.3M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $1.54 | Next Earning Date: | 11-13-2024 |
| Revenue: | $16,760,000 | Revenue Growth: | 303.27% |
| Revenue Growth (this year): | 67.95% | Revenue Growth (next year): | -6.58% |
Latest Vaxart Inc News
VXRT Breaking Stock News: Dive into VXRT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Vaxart Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
3 days ago
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...
Zacks
4 days ago
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
4 days ago
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
10 days ago
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13
Simply Wall St.
17 days ago
Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain
GlobeNewswire
24 days ago
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
GlobeNewswire
a month ago
Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need
Compare VXRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VXRT Vaxart Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.